ArticleTissue engineering. Part A2011
Delivery of plasmid DNA encoding bone morphogenetic protein-2 with a biodegradable branched polycationic polymer in a critical-size rat cranial defect model.
Article in Tissue engineering. Part A, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 45 citations in OpenAlex.
- A green-electrospun nanofibrous scaffold incorporating polyethylenimine-modified liposomes for sustained BMP2 gene delivery and enhanced osteogenic differentiation.Frontiers in bioengineering and biotechnology · 2026Article
- Bioactive Materials for Bone Regeneration: Biomolecules and Delivery Systems.ACS biomaterials science & engineering · 2023Review
- Emerging local delivery strategies to enhance bone regeneration.Biomedical materials (Bristol, England) · 2020Review
- Non-viral Gene Delivery Methods for Bone and Joints.Frontiers in bioengineering and biotechnology · 2020Review
- Biomaterial-based delivery systems of nucleic acid for regenerative research and regenerative therapy.Regenerative therapy · 2019Review
- BMP-2 Gene Delivery-Based Bone Regeneration in Dentistry.Pharmaceutics · 2019Review
- Non-viral gene delivery systems for tissue repair and regeneration.Journal of translational medicine · 2018Review
- Bone Regeneration Using Gene-Activated Matrices.The AAPS journal · 2017Review
- Gene therapy for bone tissue engineering.Tissue engineering and regenerative medicine · 2016Article
- Biodegradable, phosphate-containing, dual-gelling macromers for cellular delivery in bone tissue engineering.Biomaterials · 2015Article
- Osteochondral tissue regeneration through polymeric delivery of DNA encoding for the SOX trio and RUNX2.Acta biomaterialia · 2014Article
- Sustained localized presentation of RNA interfering molecules from in situ forming hydrogels to guide stem cell osteogenic differentiation.Biomaterials · 2014Article
- Physical non-viral gene delivery methods for tissue engineering.Annals of biomedical engineering · 2013Review
- Evaluation of bone regeneration using the rat critical size calvarial defect.Nature protocols · 2012Article
- Building bridges: leveraging interdisciplinary collaborations in the development of biomaterials to meet clinical needs.Advanced materials (Deerfield Beach, Fla.) · 2012Review
- Gene delivery to bone.Advanced drug delivery reviews · 2012Review
- Bone tissue engineering: recent advances and challenges.Critical reviews in biomedical engineering · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
This study investigated the delivery of plasmid DNA (pDNA) encoding bone morphogenetic protein-2 in the form of polyplexes with a biodegradable branched triacrylate/amine polycationic polymer (TAPP) that were complexed with gelatin microparticles (GMPs) loaded within a porous tissue engineering scaffold. More specifically, the study investigated the interplay between TAPP degradation, gelatin degradation, pDNA release, and bone formation in a critical-size rat cranial defect model. The pDNA release kinetics in vitro were not affected by the crosslinking density of the GMPs but depended, rather, on the degradation rates of the TAPPs. Besides the initial release of polyplexes not bound to the GMPs and the minimal release of polyplexes through diffusion or dissociation from the GMPs, the pDNA was likely released as naked pDNA or as part of an incomplete polyplex, after the degradation of fragments of the polycationic polymer. After 30 days, significantly higher amounts of pDNA were released (93%-98%) from composite scaffolds containing naked pDNA or pDNA complexed with P-AEPZ (synthesized with 1-[2-aminoethyl]piperazine, a faster degrading TAPP) compared with those containing pDNA complexed with P-DED (synthesized with N,N-dimethylethylenediamine, a slower degrading TAPP) (74%-82%). Composite scaffolds containing GMPs complexed with TAPP/pDNA polyplexes did not result in enhanced bone formation, as analyzed by microcomputed tomography and histology, in a critical-size rat cranial defect at 12 weeks postimplantation compared with those loaded with naked pDNA. The results demonstrate that polycationic polymers with a slow degradation rate can prolong the release of pDNA from the composite scaffolds and suggest that a gene delivery system comprising biodegradable polycationic polymers should be designed to release the pDNA in an intact polyplex form.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.